Atezolizumab Plus Bevacizumab Combination Therapy Compared to Sorafenib and Atezolizumab Monotherapies for Treatment of Unresectable or Metastatic Hepatocellular Carcinoma

Background/Aim

Sorafenib has been the historical first-line treatment of choice for unresectable or metastatic hepatocellular carcinoma (HCC) since 2007.

However, on May 29, 2020, FDA approved atezolizumab plus bevacizumab (AB) combination for HCC and gave it priority over sorafenib.

Here, we performed a systematic review evaluating the efficacy and safety of combination immunogenic chemotherapy as first-line therapy as opposed to sorafenib (S) and atezolizumab (A) monotherapies.

Report Access / View File

Overall Rating

0

5 Star

(0)

4 Star

(0)

3 Star

(0)

2 Star

(0)

1 Star

(0)

APA

GUDAPATI, S. (2021). Atezolizumab Plus Bevacizumab Combination Therapy Compared to Sorafenib and Atezolizumab Monotherapies for Treatment of Unresectable or Metastatic Hepatocellular Carcinoma. Afribary. Retrieved from https://afribary.com/works/apdworale-posterpresentationbyprathima

MLA 8th

GUDAPATI, SRAVYA "Atezolizumab Plus Bevacizumab Combination Therapy Compared to Sorafenib and Atezolizumab Monotherapies for Treatment of Unresectable or Metastatic Hepatocellular Carcinoma" Afribary. Afribary, 25 Aug. 2021, https://afribary.com/works/apdworale-posterpresentationbyprathima. Accessed 22 Nov. 2024.

MLA7

GUDAPATI, SRAVYA . "Atezolizumab Plus Bevacizumab Combination Therapy Compared to Sorafenib and Atezolizumab Monotherapies for Treatment of Unresectable or Metastatic Hepatocellular Carcinoma". Afribary, Afribary, 25 Aug. 2021. Web. 22 Nov. 2024. < https://afribary.com/works/apdworale-posterpresentationbyprathima >.

Chicago

GUDAPATI, SRAVYA . "Atezolizumab Plus Bevacizumab Combination Therapy Compared to Sorafenib and Atezolizumab Monotherapies for Treatment of Unresectable or Metastatic Hepatocellular Carcinoma" Afribary (2021). Accessed November 22, 2024. https://afribary.com/works/apdworale-posterpresentationbyprathima

Atezolizumab Plus Bevacizumab Combination Therapy Compared to Sorafenib and Atezolizumab Monotherapies for Treatment of Unresectable or Metastatic Hepatocellular Carcinoma

0

Document Details

Related Works